Polarean Imaging (POLX ) has expanded its representative agreement with Ascend Imaging, extending coverage into additional US states. The non-exclusive partnership now spans 19 states, up from four in the original June 2025 agreement.
Ascend Imaging will continue to act as an independent manufacturer’s representative supporting the promotion and sale of Polarean’s Xenon MRI platform. The team will complement Polarean’s commercial team by identifying prospective customers, driving engagement, and supporting negotiations through to closure.
Polarean is a leader in the field of hyperpolarisation science and has successfully developed the hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW®, which is FDA-approved in the United States.
This drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations.
Polarean’s Chief Executive Officer Christopher von Jako, Ph.D said: “Our collaboration with Ascend Imaging has already proven highly productive, and we see clear value in their ability to connect us with the right decision-makers at leading institutions.
“By expanding this partnership into additional states, we can further strengthen our commercial reach and accelerate adoption of Xenon MRI, advancing our mission to transform pulmonary medicine and ultimately improving outcomes for patients across the country.”
Ascend Imaging specialises in radiology and radiation oncology solutions, including advanced imaging hardware and artificial intelligence technologies.
The company’s long-standing relationships with healthcare providers align with Polarean’s targeted expansion in functional lung imaging.
Ascend Imaging’s President Wesley Adams said: “Xenon MRI is gaining momentum as institutions recognise the value of regional functional lung imaging.
“With hospitals increasingly seeking innovative solutions that are supported by reimbursement, we are excited to expand our partnership with Polarean and help bring this important technology to more patients and providers.”
View from Vox
Expanding from four to 19 states materially broadens Polarean’s top-of-funnel reach while keeping fixed sales costs lean via a representative model. It signals early traction since the June partnership and should help shorten sales cycles as awareness of Xenon MRI grows.